Anke Biotech announced that the clinical trial application for AK2405, an innovative drug developed independently by the company, was accepted by the State Drug Administration. This product is an antibody-conjugated drug targeting HER2. It is registered and classified as a therapeutic biological product class 1. The proposed indication is advanced malignant solid tumors. Preclinical studies have shown that it has high specificity and high anti-tumor activity. This acceptance is only a phased result of the development of a new drug, and there is still uncertainty about whether it will be approved for clinical trials and marketing.

Anke Biotech announced that the clinical trial application for AK2405, an innovative drug developed independently by the company, was accepted by the State Drug Administration. This product is an antibody-conjugated drug targeting HER2. It is registered and classified as a therapeutic biological product class 1. The proposed indication is advanced malignant solid tumors. Preclinical studies have shown that it has high specificity and high anti-tumor activity. This acceptance is only a phased result of the development of a new drug, and there is still uncertainty about whether it will be approved for clinical trials and marketing.